• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    5/20/22 4:37:55 PM ET
    $OTRA
    Get the next $OTRA alert in real time by email
    SC 13G/A 1 tm2215573d1_sc13ga.htm SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G/A
    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

    OTR Acquisition Corp.
    (Name of Issuer)
    Class A Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    67113Q 105**
    (CUSIP Number)
    May 20, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ¨ Rule 13d-1(b)
      ¨ Rule 13d-1(c)
      x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **The CUSIP number for the Units which include the Common Stock is 67113Q 204 and the CUSIP number for the Warrants is 67113Q 113.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     
     

     

    CUSIP No. 67113Q 105  13G  Page 2 of 7 Pages

     

    1. NAMES OF REPORTING PERSONS
    OTR Acquisition Sponsor LLC
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (a) ☐
    (b) ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF

    SHARES
    BENEFICIALLY
    OWNED BY

    5. SOLE VOTING POWER
    0
    6. SHARED VOTING POWER
    0
    EACH
    REPORTING
    PERSON WITH
    7. SOLE DISPOSITIVE POWER
    0
    8.

    SHARED DISPOSITIVE POWER

    0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
      (See Instructions) ☐
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0%
    12. TYPE OF REPORTING PERSON (See Instructions)
    OO
           
               

    * The securities are held directly by OTR Acquisition Sponsor LLC (the “Sponsor”), which, as of May 18, 2022, is managed by a board of managers consisting of three persons, which has sole voting and dispositive control of the securities held by the Sponsor. On May 6, 2022, the Sponsor transferred an aggregate of 1,305,920 shares of Class B common stock, par value U.S. $0.0001 per share (the “Class B Common Stock”), of OTR Acquisition Corp. (“OTR”) previously held by the Sponsor to certain members of the Sponsor. In connection with the consummation of OTR’s business combination with Comera Life Sciences Holdings, Inc. (“Holdco”), a Delaware corporation, on May 19, 2022, the 1,305,918 shares of Class B Common Stock held by the Sponsor converted into 1,305,918 shares of Class A Common Stock of OTR and such shares were exchanged for 1,305,918 shares of Holdco common stock.

     
     

     

    CUSIP No. 67113Q 105  13G   Page 3 of 7 Pages

     

    1. NAMES OF REPORTING PERSONS
    Nicholas J. Singer
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (a) ☐
    (b) ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America

    NUMBER OF

    SHARES
    BENEFICIALLY
    OWNED BY

    5. SOLE VOTING POWER
    0
    6.

    SHARED VOTING POWER

    0

    EACH
    REPORTING
    PERSON WITH
    7. SOLE DISPOSITIVE POWER
    0
    8.

    SHARED DISPOSITIVE POWER

    0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0*
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
      (See Instructions) ☐
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0%*
    12. TYPE OF REPORTING PERSON (See Instructions)
    IN
           
               

    * The securities are held indirectly by Nicholas J. Singer, who has sole voting and dispositive control of PC SPAC Holdings LLC, which holds the securities directly. Prior to May 18, 2022, Mr. Singer was the sole managing member of the Sponsor. and Chief Executive Officer and Chairman of the Issuer. On May 1218, 2022, the Sponsor entered into a certain second amended and restated limited liability operating agreement, provides that the Sponsor be managed by a board of managers consisting of three persons, including Mr. Singer. ForIn connection with the purposes of Rule 13d-3, Mr. Singer is no longer a beneficial owner ofconsummation of OTR’s business combination with Holdco, on May 19, 2022, the 1,305,918421,759 shares of Class B common stock, par value U.S. $0.0001 per share, of OTR Acquisition Corp.Common Stock held directly by the Sponsor, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest thereinMr. Singer converted into 421,759 shares of Class A Common Stock of OTR and such shares were exchanged for 421,759 shares of Holdco common stock.

     

     
     

     

    CUSIP No. 67113Q 105 13G Page 4 of 7 Pages

     

    Item 1(a).Name of Issuer:

    OTR Acquisition Corp. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    1395 Brickell Avenue, Suite 800, Miami, FL 33131

     

    Item 2(a).

    Name of Person Filing:

    This statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

      (i) OTR Acquisition Sponsor LLC
      (ii) Nicholas J. Singer

     

    Item 2(b).

     

    Address of Principal Business Office or, if None, Residence:

    The principal business address of each of the Reporting Persons is 1395 Brickell Avenue, Suite 800, Miami, FL 33131.

     

    Item 2(c).

     

    Citizenship:

    OTR Acquisition Sponsor, LLC is a Delaware limited liability company, and Nicholas J. Singer is a citizen of the United States of America.

     

    Item 2(d).

     

    Title of Class of Securities:

    Class A Common Stock, par value $0.0001 per share (the “Shares”).

     

    Item 2(e).

     

    CUSIP Number:

    67113Q 105

     

    Item 3.

     

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨  Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable.

     

    Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

    Disclosure for each Reporting Person:

     

     
     

     

    CUSIP No. 67113Q 105 13G Page 5 of 7 Pages

     

    (a)

    Amount beneficially owned:

    OTR Acquisition Sponsor LLC – 0 Shares

    Nicholas J. Singer – 0 Shares

       

    (b)

    Percent of class:

    OTR Acquisition Sponsor LLC – 0%

    Nicholas J. Singer – 0%

       

    (c)

    Number of shares as to which the person has:

       
      (i)

    Sole power to vote or to direct the vote:

    OTR Acquisition Sponsor LLC – 0

    Nicholas J. Singer – 0

      (ii)

    Shared power to vote or to direct the vote:

    OTR Acquisition Sponsor LLC – 0 Shares

    Nicholas J. Singer – 0 Shares

      (iii)

    Sole power to dispose or to direct the disposition of:

    OTR Acquisition Sponsor LLC – 0

    Nicholas J. Singer – 0

      (iv)

    Shared power to dispose or to direct the disposition of:

    OTR Acquisition Sponsor LLC – 0 Shares

    Nicholas J. Singer – 0 Shares

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x*.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

     

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10. Certifications.

    Not Applicable.

     

     
     

     

    CUSIP No. 67113Q 105 13G Page 6 of 7 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: May 20, 2022

         
     

    OTR ACQUISITION SPONSOR LLC

     

    PC SPAC HOLDINGS, its Manager

    By: Purchase Capital Investments LLC, its sole member

    By: Purchase Capital LLC, its sole member

         
         
      By: /s/ Nicholas J. Singer
        Name: Nicholas J. Singer
        Title: Authorized Signatory
         
        /s/ Nicholas J. Singer
        Name: Nicholas J. Singer

     

     

     

    Get the next $OTRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Gray Glenn Evan converted options into 22,123 shares and disposed of 100,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:37:26 PM ET
    $OTRA

    SEC Form 4: Otr Acquisition Sponsor Llc converted options into 1,305,918 shares and disposed of 1,305,918 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:35:50 PM ET
    $OTRA

    SEC Form 4: Besner Nadav converted options into 5,000 shares and disposed of 5,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:36:27 PM ET
    $OTRA

    $OTRA
    SEC Filings

    View All

    SEC Form 15-12B filed by OTR Acquisition Corp.

    15-12B - OTR Acquisition Corp. (0001821318) (Filer)

    5/31/22 8:00:30 AM ET
    $OTRA

    OTR Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OTR Acquisition Corp. (0001821318) (Filer)

    5/24/22 4:31:11 PM ET
    $OTRA

    SEC Form 25-NSE filed by OTR Acquisition Corp.

    25-NSE - OTR Acquisition Corp. (0001821318) (Subject)

    5/19/22 4:06:33 PM ET
    $OTRA

    $OTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics

    – Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb

    5/20/22 8:00:00 AM ET
    $OTRA
    $OTRAU
    Business Services
    Finance

    Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation

    Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c

    5/9/22 8:00:00 AM ET
    $OTRA

    Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo

    Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202

    4/27/22 8:00:00 AM ET
    $OTRA

    $OTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    1/24/23 9:57:09 AM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/20/22 4:37:55 PM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/10/22 4:19:44 PM ET
    $OTRA